Skip to main content
Top
Published in: European Journal of Nutrition 3/2018

Open Access 01-04-2018 | Original Contribution

Analysis of different innovative formulations of curcumin for improved relative oral bioavailability in human subjects

Authors: Martin Purpura, Ryan P. Lowery, Jacob M. Wilson, Haider Mannan, Gerald Münch, Valentina Razmovski-Naumovski

Published in: European Journal of Nutrition | Issue 3/2018

Login to get access

Abstract

Purpose

The optimal health benefits of curcumin are limited by its low solubility in water and corresponding poor intestinal absorption. Cyclodextrins (CD) can form inclusion complexes on a molecular basis with lipophilic compounds, thereby improving aqueous solubility, dispersibility, and absorption. In this study, we investigated the bioavailability of a new γ-cyclodextrin curcumin formulation (CW8). This formulation was compared to a standardized unformulated curcumin extract (StdC) and two commercially available formulations with purported increased bioavailability: a curcumin phytosome formulation (CSL) and a formulation of curcumin with essential oils of turmeric extracted from the rhizome (CEO).

Methods

Twelve healthy human volunteers participated in a double-blinded, cross-over study. The plasma concentrations of the individual curcuminoids that are present in turmeric (namely curcumin, demethoxycurcumin, and bisdemethoxycurcumin) were determined at baseline and at various intervals after oral administration over a 12-h period.

Results

CW8 showed the highest plasma concentrations of curcumin, demethoxycurcumin, and total curcuminoids, whereas CSL administration resulted in the highest levels of bisdemethoxycurcumin. CW8 (39-fold) showed significantly increased relative bioavailability of total curcuminoids (AUC0−12) in comparison with the unformulated StdC.

Conclusion

The data presented suggest that γ-cyclodextrin curcumin formulation (CW8) significantly improves the absorption of curcuminoids in healthy humans.
Literature
2.
go back to reference Venigalla M, Gyengesi E, Münch G (2015) Curcumin and Apigenin—novel and promising therapeutics against chronic neuroinflammation in Alzheimer’s disease. Neural Regen Res 10(8):1181–1185. doi:10.4103/1673-5374.162686 CrossRef Venigalla M, Gyengesi E, Münch G (2015) Curcumin and Apigenin—novel and promising therapeutics against chronic neuroinflammation in Alzheimer’s disease. Neural Regen Res 10(8):1181–1185. doi:10.​4103/​1673-5374.​162686 CrossRef
3.
go back to reference Venigalla M, Sonego S, Gyengesi E, Sharman MJ, Münch G (2015) Novel promising therapeutics against chronic neuroinflammation and neurodegeneration in Alzheimer’s disease. Neurochem Int. doi:10.1016/j.neuint.2015.10.011 Venigalla M, Sonego S, Gyengesi E, Sharman MJ, Münch G (2015) Novel promising therapeutics against chronic neuroinflammation and neurodegeneration in Alzheimer’s disease. Neurochem Int. doi:10.​1016/​j.​neuint.​2015.​10.​011
4.
go back to reference Bharti AC, Donato N, Aggarwal BB (2003) Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 171(7):3863–3871CrossRef Bharti AC, Donato N, Aggarwal BB (2003) Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 171(7):3863–3871CrossRef
5.
go back to reference Karunaweera N, Raju R, Gyengesi E, Münch G (2015) Plant polyphenols as inhibitors of NF-kappaB induced cytokine production-a potential anti-inflammatory treatment for Alzheimer’s disease? Front Mol Neurosci 8:24. doi:10.3389/fnmol.2015.00024 CrossRef Karunaweera N, Raju R, Gyengesi E, Münch G (2015) Plant polyphenols as inhibitors of NF-kappaB induced cytokine production-a potential anti-inflammatory treatment for Alzheimer’s disease? Front Mol Neurosci 8:24. doi:10.​3389/​fnmol.​2015.​00024 CrossRef
6.
go back to reference Millington C, Sonego S, Karunaweera N, Rangel A, Aldrich-Wright JR, Campbell IL, Gyengesi E, Münch G (2014) Chronic neuroinflammation in Alzheimer’s disease: new perspectives on animal models and promising candidate drugs. Biomed Res Int 2014:309129. doi:10.1155/2014/309129 CrossRef Millington C, Sonego S, Karunaweera N, Rangel A, Aldrich-Wright JR, Campbell IL, Gyengesi E, Münch G (2014) Chronic neuroinflammation in Alzheimer’s disease: new perspectives on animal models and promising candidate drugs. Biomed Res Int 2014:309129. doi:10.​1155/​2014/​309129 CrossRef
7.
go back to reference Hansen E, Krautwald M, Maczurek AE, Stuchbury G, Fromm P, Steele M, Schulz O, Garcia OB, Castillo J, Korner H, Münch G (2010) A versatile high throughput screening system for the simultaneous identification of anti-inflammatory and neuroprotective compounds. J Alzheimer’s Dis 19(2):451–464. doi:10.3233/JAD-2010-1233 CrossRef Hansen E, Krautwald M, Maczurek AE, Stuchbury G, Fromm P, Steele M, Schulz O, Garcia OB, Castillo J, Korner H, Münch G (2010) A versatile high throughput screening system for the simultaneous identification of anti-inflammatory and neuroprotective compounds. J Alzheimer’s Dis 19(2):451–464. doi:10.​3233/​JAD-2010-1233 CrossRef
9.
go back to reference Lev-Ari S, Maimon Y, Strier L, Kazanov D, Arber N (2006) Down-regulation of prostaglandin E2 by curcumin is correlated with inhibition of cell growth and induction of apoptosis in human colon carcinoma cell lines. J Soc Integr Oncol 4(1):21–26 Lev-Ari S, Maimon Y, Strier L, Kazanov D, Arber N (2006) Down-regulation of prostaglandin E2 by curcumin is correlated with inhibition of cell growth and induction of apoptosis in human colon carcinoma cell lines. J Soc Integr Oncol 4(1):21–26
10.
go back to reference Abe Y, Hashimoto S, Horie T (1999) Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacol Res Off J Italian Pharmacol Soc 39(1):41–47. doi:10.1006/phrs.1998.0404 Abe Y, Hashimoto S, Horie T (1999) Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacol Res Off J Italian Pharmacol Soc 39(1):41–47. doi:10.​1006/​phrs.​1998.​0404
11.
go back to reference Asher GN, Spelman K (2013) Clinical utility of curcumin extract. Altern Ther Health Med 19(2):20–22 Asher GN, Spelman K (2013) Clinical utility of curcumin extract. Altern Ther Health Med 19(2):20–22
12.
go back to reference Bhattacharyya S, Mandal D, Saha B, Sen GS, Das T, Sa G (2007) Curcumin prevents tumor-induced T cell apoptosis through Stat-5a-mediated Bcl-2 induction. J Biol Chem 282(22):15954–15964. doi:10.1074/jbc.M608189200 CrossRef Bhattacharyya S, Mandal D, Saha B, Sen GS, Das T, Sa G (2007) Curcumin prevents tumor-induced T cell apoptosis through Stat-5a-mediated Bcl-2 induction. J Biol Chem 282(22):15954–15964. doi:10.​1074/​jbc.​M608189200 CrossRef
13.
go back to reference Chandran B, Goel A (2012) A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res PTR 26(11):1719–1725. doi:10.1002/ptr.4639 CrossRef Chandran B, Goel A (2012) A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res PTR 26(11):1719–1725. doi:10.​1002/​ptr.​4639 CrossRef
17.
go back to reference Wahlstrom B, Blennow G (1978) A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol (Copenh) 43(2):86–92CrossRef Wahlstrom B, Blennow G (1978) A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol (Copenh) 43(2):86–92CrossRef
18.
go back to reference Schiborr C, Kocher A, Behnam D, Jandasek J, Toelstede S, Frank J (2014) The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes. Mol Nutr Food Res 58(3):516–527. doi:10.1002/mnfr.201300724 CrossRef Schiborr C, Kocher A, Behnam D, Jandasek J, Toelstede S, Frank J (2014) The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes. Mol Nutr Food Res 58(3):516–527. doi:10.​1002/​mnfr.​201300724 CrossRef
20.
go back to reference Holder GM, Plummer JL, Ryan AJ (1978) The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat. Xenobiotica 8(12):761–768CrossRef Holder GM, Plummer JL, Ryan AJ (1978) The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat. Xenobiotica 8(12):761–768CrossRef
21.
go back to reference Ireson C, Orr S, Jones DJ, Verschoyle R, Lim CK, Luo JL, Howells L, Plummer S, Jukes R, Williams M, Steward WP, Gescher A (2001) Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res 61(3):1058–1064 Ireson C, Orr S, Jones DJ, Verschoyle R, Lim CK, Luo JL, Howells L, Plummer S, Jukes R, Williams M, Steward WP, Gescher A (2001) Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res 61(3):1058–1064
22.
go back to reference Hassaninasab A, Hashimoto Y, Tomita-Yokotani K, Kobayashi M (2011) Discovery of the curcumin metabolic pathway involving a unique enzyme in an intestinal microorganism. Proc Natl Acad Sci USA 108(16):6615–6620. doi:10.1073/pnas.1016217108 CrossRef Hassaninasab A, Hashimoto Y, Tomita-Yokotani K, Kobayashi M (2011) Discovery of the curcumin metabolic pathway involving a unique enzyme in an intestinal microorganism. Proc Natl Acad Sci USA 108(16):6615–6620. doi:10.​1073/​pnas.​1016217108 CrossRef
23.
go back to reference Vareed SK, Kakarala M, Ruffin MT, Crowell JA, Normolle DP, Djuric Z, Brenner DE (2008) Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev 17(6):1411–1417. doi:10.1158/1055-9965.EPI-07-2693 CrossRef Vareed SK, Kakarala M, Ruffin MT, Crowell JA, Normolle DP, Djuric Z, Brenner DE (2008) Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev 17(6):1411–1417. doi:10.​1158/​1055-9965.​EPI-07-2693 CrossRef
24.
25.
go back to reference Szejtli J (1994) Medicinal applications of cyclodextrins. Med Res Rev 14(3):353–386CrossRef Szejtli J (1994) Medicinal applications of cyclodextrins. Med Res Rev 14(3):353–386CrossRef
27.
go back to reference Ikeda S, Uchida T, Ichikawa T, Watanabe T, Uekaji Y, Nakata D, Terao K, Yano T (2010) Complexation of tocotrienol with gamma-cyclodextrin enhances intestinal absorption of tocotrienol in rats. Biosci Biotechnol Biochem 74(7):1452–1457. doi:10.1271/bbb.100137 CrossRef Ikeda S, Uchida T, Ichikawa T, Watanabe T, Uekaji Y, Nakata D, Terao K, Yano T (2010) Complexation of tocotrienol with gamma-cyclodextrin enhances intestinal absorption of tocotrienol in rats. Biosci Biotechnol Biochem 74(7):1452–1457. doi:10.​1271/​bbb.​100137 CrossRef
28.
go back to reference Terao K, Nakata D, Fukumi H, Schmid G, Arima H, Hirayama F, Uekama K (2006) Enhancement of oral bioavailability of coenzyme Q10 by complexation with gamma-cyclodextrin in healthy adults. Nutr Res 26:503–508CrossRef Terao K, Nakata D, Fukumi H, Schmid G, Arima H, Hirayama F, Uekama K (2006) Enhancement of oral bioavailability of coenzyme Q10 by complexation with gamma-cyclodextrin in healthy adults. Nutr Res 26:503–508CrossRef
29.
go back to reference Cuomo J, Appendino G, Dern AS, Schneider E, McKinnon TP, Brown MJ, Togni S, Dixon BM (2011) Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J Nat Prod 74(4):664–669. doi:10.1021/np1007262 CrossRef Cuomo J, Appendino G, Dern AS, Schneider E, McKinnon TP, Brown MJ, Togni S, Dixon BM (2011) Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J Nat Prod 74(4):664–669. doi:10.​1021/​np1007262 CrossRef
30.
go back to reference Wakabayashi M, Fishman WH (1961) A method for freeing Helix pomatia beta-glucuronidase of sulfatase by simple heat denaturation. Biochim Biophys Acta 48:195–197CrossRef Wakabayashi M, Fishman WH (1961) A method for freeing Helix pomatia beta-glucuronidase of sulfatase by simple heat denaturation. Biochim Biophys Acta 48:195–197CrossRef
32.
go back to reference Liu A, Lou H, Zhao L, Fan P (2006) Validated LC/MS/MS assay for curcumin and tetrahydrocurcumin in rat plasma and application to pharmacokinetic study of phospholipid complex of curcumin. J Pharm Biomed Anal 40(3):720–727. doi:10.1016/j.jpba.2005.09.032 CrossRef Liu A, Lou H, Zhao L, Fan P (2006) Validated LC/MS/MS assay for curcumin and tetrahydrocurcumin in rat plasma and application to pharmacokinetic study of phospholipid complex of curcumin. J Pharm Biomed Anal 40(3):720–727. doi:10.​1016/​j.​jpba.​2005.​09.​032 CrossRef
34.
go back to reference Antony B, Merina B, Iyer VS, Judy N, Lennertz K, Joyal S (2008) A pilot cross-over study to evaluate human oral bioavailability of BCM-95CG (Biocurcumax), a novel bioenhanced preparation of curcumin. Indian J Pharm Sci 70(4):445–449. doi:10.4103/0250-474X.44591 CrossRef Antony B, Merina B, Iyer VS, Judy N, Lennertz K, Joyal S (2008) A pilot cross-over study to evaluate human oral bioavailability of BCM-95CG (Biocurcumax), a novel bioenhanced preparation of curcumin. Indian J Pharm Sci 70(4):445–449. doi:10.​4103/​0250-474X.​44591 CrossRef
35.
go back to reference Sasaki H, Sunagawa Y, Takahashi K, Imaizumi A, Fukuda H, Hashimoto T, Wada H, Katanasaka Y, Kakeya H, Fujita M, Hasegawa K, Morimoto T (2011) Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull 34(5):660–665CrossRef Sasaki H, Sunagawa Y, Takahashi K, Imaizumi A, Fukuda H, Hashimoto T, Wada H, Katanasaka Y, Kakeya H, Fujita M, Hasegawa K, Morimoto T (2011) Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull 34(5):660–665CrossRef
37.
go back to reference Lao CD, Ruffin MTt, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL, Brenner DE (2006) Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 6:10. doi:10.1186/1472-6882-6-10 CrossRef Lao CD, Ruffin MTt, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL, Brenner DE (2006) Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 6:10. doi:10.​1186/​1472-6882-6-10 CrossRef
38.
go back to reference Dadhaniya P, Patel C, Muchhara J, Bhadja N, Mathuria N, Vachhani K, Soni MG (2011) Safety assessment of a solid lipid curcumin particle preparation: acute and subchronic toxicity studies. Food Chem Toxicol Int J Publ Br Ind Biol Res Assoc 49(8):1834–1842. doi:10.1016/j.fct.2011.05.001 CrossRef Dadhaniya P, Patel C, Muchhara J, Bhadja N, Mathuria N, Vachhani K, Soni MG (2011) Safety assessment of a solid lipid curcumin particle preparation: acute and subchronic toxicity studies. Food Chem Toxicol Int J Publ Br Ind Biol Res Assoc 49(8):1834–1842. doi:10.​1016/​j.​fct.​2011.​05.​001 CrossRef
Metadata
Title
Analysis of different innovative formulations of curcumin for improved relative oral bioavailability in human subjects
Authors
Martin Purpura
Ryan P. Lowery
Jacob M. Wilson
Haider Mannan
Gerald Münch
Valentina Razmovski-Naumovski
Publication date
01-04-2018
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nutrition / Issue 3/2018
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI
https://doi.org/10.1007/s00394-016-1376-9

Other articles of this Issue 3/2018

European Journal of Nutrition 3/2018 Go to the issue